Stockreport
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen, Inc. (OCGN)
More Company Research
Source: GlobeNewswire
PDF
OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophth
[Read more]
IMPACT SNAPSHOT
EVENT TIME:
{{FirstSection.LastPriceAtNewsEventTime2}}
OCGN
Last Price
{{SecondSection.LastPrice}}
Price Change
{{SecondSection.PriceChange}} {{SecondSection.PriceChangeTriangle_AMP}}
Price Change %
{{SecondSection.PriceChangePercent}} {{SecondSection.PriceChangeTriangle_AMP}}
Volume Shares
{{SecondSection.Volume}}
Max Up
{{SecondSection.MaxUp}}
Max Down
{{SecondSection.MaxDown}}
Volume Ratio
{{SecondSection.VolumeImpactStr_AMP}}%
{{SecondSection.PriceChangePercent}}
Don't Miss Out On The Next BIG Stock Move
{{GreenBoxData.Blurb}}
Performance comparison
Updated
{{SecondSection.VwapEventTime}}
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST PRICE AT
NEWS EVENT {{SecondSection.LastPriceAtNewsEvent}}
|
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
{{FirstSection.LastPrice}}
|
LAST PRICE |
{{SecondSection.LastPrice}}
|
|
{{FirstSection.VWapStr_AMP}}
{{FirstSection.VwapEventTime}}
|
VWAP |
{{SecondSection.VWapStr_AMP}}
{{SecondSection.VwapEventTime}}
|
|
{{FirstSection.MaxUp}}
High: {{FirstSection.EodHigh}}
|
MAX UP |
{{SecondSection.MaxUp}}
High: {{SecondSection.EodHigh}}
|
|
{{FirstSection.MaxDown}}
Low: {{FirstSection.EodLow}}
|
MAX DOWN |
{{SecondSection.MaxDown}}
Low: {{SecondSection.EodLow}}
|
|
{{FirstSection.TodaysRangeStr_AMP}}
{{FirstSection.RangEvg}}
|
POST NEWS RANGE |
{{SecondSection.TodaysRangeStr_AMP}}
{{SecondSection.RangEvg}}
|
|
{{FirstSection.PriceChange}}
{{FirstSection.PriceChangeTriangle_AMP}}
|
PRICE CHANGE |
{{SecondSection.PriceChange}}
{{SecondSection.PriceChangeTriangle_AMP}}
|
|
{{FirstSection.PriceChangePercent}}
|
PRICE CHANGE PERCENTAGE |
{{SecondSection.PriceChangePercent}}
|
|
{{FirstSection.Spx500}}
|
S&P 500 (SPX) |
{{SecondSection.Spx500}}
|
|
{{FirstSection.VolumeImpactStr_AMP}}
|
VOLUME RATIO |
{{SecondSection.VolumeImpactStr_AMP}}
|
|
{{FirstSection.Volume}}
|
VOLUME (SHARES) |
{{SecondSection.Volume}}
|
|
{{FirstSection.TicksString}}
|
TICKS |
{{SecondSection.TicksString}}
|
|
{{FirstSection.AvgTransactionSizeStr_AMP}}
|
AVG SHARES PER TRADE |
{{SecondSection.AvgTransactionSizeStr_AMP}}
|
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY